Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 05, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 1,620,000 ordinary shares.
- Purchase Price: 1,328.73 pence per share.
- Treasury Holdings: 424,439,158 shares (representing 7.58% of total voting rights).
- Shares in Issue: 5,599,881,255 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the acquisition of 1,620,000 shares on October 05, 2007. This transaction was executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007. The acquired shares are held in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,599,881,255) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (424,439,158) and its impact on the total voting rights percentage (7.58%).
- Note that this filing is a notification of a specific transaction and does not include periodic financial performance data.